Therapeutic areas

More filters

Favourite

Popular

Promote

Welcome to Servier's content hub for healthcare professionals

Trending

Cardiometabolism 16.01.2025

My Health Partner, the ideal partner to help patients understand their disease better and improve their everyday lifestyle! Learn more

My Health Partner, the ideal partner to help patients understand their disease better and improve their everyday lifestyle!

0:29

Trending

CardiometabolismOncologyVenous Disease 03.06.2025

Welcome to My Servier Middle East Portal Learn more

Welcome to My Servier Middle East Portal

0:54

Discover more articles, guidelines and events.

Show: Favourite Popular Promoted

Filters

ACE Inhibitors vs ARBs Does Cardiovascular Protection Differ

ACE Inhibitors vs ARBs Does Cardiovascular Protection Diffe

Cardiometabolism 15.09.2026

ACE Inhibitors vs ARBs Does Cardiovascular Protection Differ

Statin Intolerance Overcoming a Barrier to LDL-C Control

Dr. Maryam Al Saeed explores statin intolerance as a potential barrier to adherence, the evidence around statin safety, and the challenges of achieving lipid targets in clinical practice.

Cardiometabolism 13.09.2026

Statin Intolerance Overcoming a Barrier to LDL-C Control

What’s New in Dyslipidemia Management The 2026 ESCEAS Focused Update

Prof. Waleed AlHabeeb highlights the 2026 focused update of the ESC/EAS Guidelines and its implications for dyslipidemia treatment and LDL-C targets.

Cardiometabolism 13.09.2026

What’s New in Dyslipidemia Management The 2026 ESCEAS Focused Update

ADD2DIA: synergy between SGLT2i and Gliglazide MR

Watch the ADD2DIA overview on the real-world clinical effectiveness of adding an SGLT2 inhibitor to gliclazide MR-based therapy in T2DM.

Cardiometabolism 13.09.2026

ADD2DIA: synergy between SGLT2i and Gliglazide MR

ADD2DIA Real-World Effectiveness of SGLT2i + Gliclazide MR

ADD2DIA: Real-World Effectiveness of SGLT2i + Gliclazide MR

Cardiometabolism 13.09.2026

ADD2DIA Real-World Effectiveness of SGLT2i + Gliclazide MR

Indapamide-Based Treatment Evidence Beyond BP Reduction

Indapamide-Based Treatment: Evidence Beyond BP Reduction

Cardiometabolism 13.09.2026

Indapamide-Based Treatment Evidence Beyond BP Reduction

PROGRESS Reducing Recurrent Stroke Risk After Stroke or TIA

PROGRESS Reducing Recurrent Stroke Risk After Stroke or TIA

Cardiometabolism 13.09.2026

PROGRESS Reducing Recurrent Stroke Risk After Stroke or TIA

Triple SPC Therapy: Why Timing Matters

Triple SPC Therapy: Why Timing Matters

Cardiometabolism 13.09.2026

Triple SPC Therapy: Why Timing Matters

Coveram: From Guidelines to BP Control

coveram: From Guidelines to BP Control

Cardiometabolism 13.09.2026

Coveram: From Guidelines to BP Control

Triplixam Triple-Action Mode of Action for BP Control

Discover how Triplixam combines perindopril, indapamide and amlodipine in a single-pill combination, targeting complementary pathways involved in blood pressure control and supporting long-term cardiovascular protection.

Cardiometabolism 12.09.2026

Triplixam Triple-Action Mode of Action for BP Control

2024 ESC Hypertension from Guideline to Treatment

Explore the 2024 ESC practical treatment algorithm, from low-dose dual combination therapy through treatment intensification and management of apparent resistant hypertension.

Cardiometabolism 12.09.2026

2024 ESC Hypertension from Guideline to Treatment

One Target, Growing Evidence: SBP <120 mmHg

One Target, Growing Evidence: SBP

Cardiometabolism 12.09.2026

One Target, Growing Evidence: SBP <120 mmHg

1
2
3
...
8

Next